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Background: Diabetic foot ulcer (DFU) is a common complication of uncontrolled diabetes 
mellitus (DM). Ulcers can be neuropathic, ischemic or neuro-ischemic.  Its impact on the 
patient can be dramatic and can lead to amputation and loss of limb function. Hyperbaric 
oxygen therapy (HBOT) is used as an adjunct treatment to hasten the healing process or 
limit the extent of the damage caused by ischemia or necrotizing fasciitis. Since patients 
respond differently to HBOT, this study was carried out to identify factors that influence their 
response to the treatment after appropriate initial selection.  
Methods: We performed a case-control study of all patients with DFU treated in the 
hyperbaric and wound care unit at the King Hamad University Hospital between January 
2013 and December 2018. Patients’ data were obtained upon patient hospital visit from 
clinical records. Various baseline factors were compared between patients with and without 
adequate HBOT treatment responses. 
Results: A total of 123 patients (cases n= 75 and controls n=48) were included in the study. 
There was no significant difference in age, gender, duration of DM, weight and body mass 
index between the groups (p>0.05). Cases group (11.9 ± 4.9 ) had higher white blood cell 
count than the control group (10.1 ± 3.7) (p=0.038). Haemoglobin level was significantly 
lower in the cases (11.4 ± 1.7 mg/dl) compared to control group (12.3 ± 1.7 mg/dl) 
(p=0.009). The number of patients who had new breakdown (19% cases and 4% control) 
and had smell wounds (45% cases and 21% control) were significantly higher in cases group 
compared to the control (p<0.03). 
Conclusion: Inflammation and haemoglobin status are major factors influencing wound 






Agtergrond: Diabeetvoetulkusse is 'n algemene komplikasie van onbeheerde diabetes 
mellitus (DM). Ulkusse kan neuropaties, ischemies of neuro-ischemies van aard wees. Die 
impak daarvan op die pasiënt kan dramaties wees en kan lei tot amputasie en verlies van 
ledemaatfunksie. Hiperbariese suurstofterapie (HST) word gebruik as aanvullende 
behandeling om die genesingsproses te versnel of om die omvang van die skade wat 
veroorsaak word deur ischemie of nekrotiserende fasciitis te beperk. Aangesien pasiënte 
verskillend reageer op HST, word hierdie studie uitgevoer om faktore te identifiseer wat hul 
reaksie op behandeling beïnvloed nadat hulle toepaslik geselekteer was 
Metodes: Ons het 'n gevals-kontrolestudie uitgevoer van alle pasiënte met 
diabeetvoetulkusse wat tussen Januarie 2013 en Desember 2018 in die hiperbariese en 
wondversorgingseenheid by die Koning Hamed Universiteits-Hospitaal behandel is. Die data 
van die pasiënte is verkry uit die kliniese notas van die hospitaal. Verskeie basislynfaktore is 
vergelyk tussen pasiënte met en sonder voldoende HST-behandelingsreaksies. 
Resultate: Altesaam 123 pasiënte (75 gevalle en 48 kontrole) is by die studie ingesluit. Daar 
was geen beduidende verskil in ouderdom, geslag, duurte van DM, gewig en 
liggaamsmassa-indeks tussen die groepe nie (p>0,05). Die gevalle (11,9 ± 4,9) het 'n hoër 
aantal witbloedselle gehad as die kontrole (10,1 ± 3,7) (p = 0,038). Die hemoglobienvlak was 
aansienlik laer in die gevalle (11,4 ± 1,7 mg/dl) in vergelyking met die kontrolegroep (12,3 ± 
1,7 mg/dl) (p = 0,009). Die aantal pasiënte wat nuwe wondafbraak gehad het (19% gevalle 
en 4% kontrole) en onwelriekende wonder gehad het (45% gevalle en 21% kontrole), was 
aansienlik hoër in die gevallegroep as die kontrolegroep (p <0,03). 
Gevolgtrekking: Inflammasie en hemoglobienstatus is die belangrikste faktore wat 
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In this chapter, the literature pertaining to Hyperbaric Oxygen Therapy (HBOT) for Diabetic 
Foot Ulcer (DFU) will be reviewed.  The chapter will firstly describe the magnitude of diabetic 
disease experienced in the world, and particularly in the Middle East.  The review will then 
discuss some complications associated with diabetes and focus on DFU as common 
complication.  An overview of the management of DFU, with a focus on HBOT will set the 
stage for the context of this study and the chapter will conclude with an overview of different 
testing modalities that are used in selecting patients with DFU for HBOT. 
 
1.1 Diabetes Mellitus and its prevalence 
 
Diabetes Mellitus (DM) is the commonest non-communicable disease, affecting a large 
proportion of the world population (1).  According to the latest statistics of the International 
Diabetes Federation (IDF) in 2017, the top five countries for the number of people with DM in 
the Middle East and North Africa are Egypt, Pakistan, the Islamic republic of Iran, Saudi 
Arabia and Sudan, respectively (2). In Bahrain, the prevalence is high and is rising over time.  
Musaiger found that the prevalence of DM in Bahraini people was 0.8% in 1980, and in 
1982, it was 10.2%(3). In 1996, Zurba and Al-Garf reported that among the Bahraini 
population the prevalence was 25.5% in men (4). In another study, Al-Zurba found a 25.5% 
prevalence of Type two Diabetes Mellitus (T2DM) among Bahraini residents who are 20 
years and older (5). Aloia and Jassim reported that T2DM among men in Bahrain had 
increased to a prevalence of 38.30%(6). 
 
DM is a heterogeneous metabolic disorder characterized by the presence of hyperglycemia 
due to impairment of insulin secretion, defective insulin action or both (7). Broadly, it is 
classified into type one and type two. However, DM could be secondary to some genetic 
mutations, exocrine disease of the pancreas or drug exposure. The diagnostic criteria of DM 
are based on both blood sampling and laboratory methods (8). The diagnosis is made if any 
of the following criteria are met: A fasting plasma glucose level of 7.0 mmol/L, glycated 
hemoglobin equal to or more than 6.5%, 2-hour plasma glucose value of ≥11.1 mmol/L in a 





1.2 Diabetes complications 
 
The chronic state of hyperglycemia in diabetics is associated with complications classified as 
macrovascular and microvascular, resulting in high morbidity and mortality. Macrovascular 
complications of diabetes include coronary heart disease, stroke and peripheral vascular 
disease. Microvascular complications, such as end-stage renal disease, retinopathy and 
neuropathy, along with lower-extremity amputations, are responsible for much of the burden 
associated with diabetes (9). Also, cancers, ageing-related outcomes (e.g. dementia), 
infections and liver disease are all linked conditions (9).  Diabetic foot ulcer is another well-
known pathological condition associated with diabetes. 
 
1.3 Diabetic Foot Ulcer (DFU) 
 
1.3.1 Definition and Incidence of DFU 
 
DFU is a full thickness skin injury, necrosis or gangrene that usually occur on the soles of 
the feet, as a result of peripheral neuropathy or peripheral arterial disease in DM patients 
(10). Diabetic gangrene is a tissue death caused by occlusion of blood vessels (ischemic 
necrosis) due to micro-emboli which are caused by peripheral vascular disease as a chronic 
complication of diabetes. 
 
Worldwide, the incidence of DFU continues to increase (11). Around one in four people with 
diabetes will develop a DFU in their lifetime (12). It seems that the prevalence of DFU is not 
accurately known, but is estimated at 4-27% of DM sufferers worldwide (13). 
 
The annual incidence of DFU or necrosis in diabetic patients is known to be about 2% to 5% 
and the lifetime risk ranges from 15% to 20% (14) (15). The high incidence of DFU 
complications increases the burden for both patients and their caregivers. The huge 
economic burden concerns governments in terms of cost of treatment, management of 
complications, disability and loss of productivity (2). 
 
The type of diabetes is one of the strongest predictors of DFU occurrence. Those diabetic 
patients who had T2DM mellitus were 2.58 times more likely to develop DFU than those who 
had T1DM (16). A possible explanation for this would be that in T2DM patients there are 
other related complications of the disease, such as mechanical deformities in the bony 
architecture of the foot, peripheral neuropathy, and atherosclerotic changes in peripheral 




oxygen, nutrient transportation, and cell detoxification resulting in ulceration in the 
extremities (16). 
 
1.3.2 Pathophysiology of DFU  
 
The pathophysiology of DFU is comprised of a number of mechanisms, including 
neuropathy, vasculopathy and infection: 
 
1.3.2.1 Diabetic Neuropathy  
 
Diabetic neuropathy is the most common cause of diabetic lower extremity ulcers and results 
in sensory, motor, and autonomic nerve dysfunction (17). With proper screening, 
approximately 75% of diabetic patients undergoing foot and ankle surgery will be found to 
have neuropathy (18). Peripheral neuropathy is commonly associated with skin breakdown 
and neuropathic fractures because of the inability to sense the trauma or an injury. The risk 
of developing a first DFU has been shown to be 7 times higher in those with moderate or 
severe sensory loss compared to patients with preservation of sensation (19). Most 
guidelines recommend the 10g monofilament for neuropathy assessment in people with 
diabetes and the inability to sense a 10g pressure is the current consensus definition of loss 
of protective sensation (20). 
 
Diabetic neuropathy can be divided into sensory, motor and autonomic peripheral 
neuropathy. Evidence for sensory neuropathy includes a reduction or loss of vibration sense 
(pallhypaesthesia) and superficial sensitivity (pressure, touch) as well as subjective 
paraesthesia (21). As the sensation of pain is substantially decreased, the risk for trauma is 
significantly higher (21).  Motoric neuropathy presents as an atrophy of small foot muscles 
resulting in toe clawing. Above all, loss of Achilles tendon reflex is an early sign of motor 
neuropathy (22). The combination of both will lead to an unequal pressure distribution and 
insecure gait. Moreover, hyperkeratosis develops due to elevated plantar pressure load. 
 
Autonomic neuropathy leads to vasomotor dysfunction resulting in arteriovenous shunts of 
subcutaneous vascular network and the secretion of sweat becomes less (23). Dysfunctional 
sweating results in dry skin and reduced protective skin function and thus increased risk of 
injury (21). Moreover, as a result of autonomic neuropathy, medial arterial sclerosis, 
Charcot’s foot (diabetic osteoarthropathy), neuropathic edema, as well as alterations of skin 






1.3.2.2 Peripheral Arterial Disease  
 
Peripheral Arterial Disease (PAD) is a major arterial disease caused by atherosclerosis (24).  
Diabetes is known as one of the most important risk factors of PAD. Diabetes is associated 
with a two- to fourfold increase in PAD incidence compared to non-diabetic individuals (25). 
PAD is an important risk factor for impaired wound healing and lower extremity amputation 
(26). Even minor injuries accompanied by infection increase the demand for blood supply 
(including nutrients, oxygen and immune system components) in the foot and an insufficient 
blood supply results in DFU, commonly leading to limb amputation (27). PAD also inhibits 
healing by disrupting the processes needed for re-epithelialization (28). In consequence, the 
American Diabetes Association recommends through consensus that the ankle-brachial 
index should be performed as a measure of detection in all diabetic individuals >50 years of 
age or those who have suffered from the disease for more than ten years (29).  
 
1.3.2.3 Diabetic Foot Infection 
 
Infection of diabetic foot can represent a dangerous complication of once it involves deeper 
soft and bone tissues (cellulitis and osteomyelitis) increasing the risk of amputation (30). The 
infection starts once the skin continuity breaks and opens a door for the bacteria to grow. 
Although most of the infections remain superficial, such as simple cellulitis, around 25% will 
spread from the epidermal layer to deeper regions, including subcutaneous tissues and 
bones, resulting in complications such as necrotic fasciitis, septic arthritis and osteomyelitis 
(31).  
The diagnosis of foot ulcers in diabetics is made by recognizing the presence of pus 
secretion from infected wounds and certain physical factors, including erythema, tenderness, 
edema and pain (32). DFU mostly appears to be polymicrobial in nature (33). Both gram-
positive (for example S.aureus, E.fecalis) and gram-negative (P.aeruginosa, E. coli, 
Klebsiella species, Proteus species, etc.) are involved in DFU. The prevalence of these 
infections in DFUs have been reported to range between 25–60% (34) (35). These different 
organisms combine together and form micro-communities within a biofilm, which is a matrix 
of extracellular polymeric substances (33). The formation of biofilm causes many infections 
to become chronic in nature. The biofilm formation is a resistance mechanism utilised by 
bacteria against the host immune system or antibiotics (36). 
 





Edmonds divides DFUs into 2 groups, namely neuropathic and neuro-ischemic (37). Since 
there is no vascular element in a neuropathic ulcer, the foot is warm, perfusion is good with a 
palpable pulse, but the perspiration is reduced, and the skin is dry and cracked. On the other 
hand, feet of neuro-ischemic ulcer patients are cold with no palpable pulse, thin skin without 
hair and the patient might give a history of intermittent claudication and rest pain may be 
present. 
 
Apart from the groups described above, a number of classification systems for DFU is known 
today, such as the Wagner classification (38), the University of Texas wound classification 
system (UT) (39), and PEDIS (considering Perfusion (ischaemia), Extent (area), Depth, 
Infection, and Sensation (neuropathy)) (40). Wagner's classification is widely used and 
describes the extent of the ulcer, but does not describe the state of ischemia (41). Infection 
is divided into mild infection (superficial, inner and limited in size), moderate (deeper and 
wider), severe (accompanied by systemic signs or metabolic disorders) (31). Criteria for the 
diagnosis of infection in DFU include swelling, induration, erythema around the lesion, local 
pain, palpable local warmth and presence of pus, where two of these criteria are enough for 
making the diagnosis (42).  
 
The UT system grades ulcers based on depth, which divides patients who have clean, 
infected and ischemic ulcers and those who have both infection and ischaemia (43). As a 
result, it has been shown that it predicts major amputation and wound healing (41). The 
PEDIS system was designed by the International Working Group of the Diabetic Foot (44). It 
differs from the UT in being designed specifically for prospective research.  
 
The International Working Group on the Diabetic Foot (IWGDF) review found a large number 
of proposed classification and scoring systems for DFUs, which suggests that none is ideal 
for routine use in populations worldwide (45). This reflects the different purposes for using a 
particular classification and scoring system, including communication among health 
professionals (independent of the level of clinical care), for purposes of clinical 
prognostication and guidance of treatment, or for clinical audit of outcomes across units and 
populations (45).  
 
 
1.3.2.5 Management of DFU 
The main goal in the management of DFU is the closure of the wound (46). Treatment of 
DFU varies depending on the severity of the ulcer and the presence or absence of ischemia. 




(“offloading”), managing the infection by providing adequate antibiotics (if required) and ulcer 
treatment using wound dressing (47) (48).  
 
The Wound Bed Preparation Paradigm provides a structured approach to wound healing 
(48). This holistic approach addresses the wound in three main aspects; treating the cause, 
addressing patient centered concerns and local wound management (49). With regards to 
DFU, an accurate diagnosis of the cause of the ulcer should be established. An acronym 
VIPs is used to identify the cause of DFU (49). The etiology of DFU considered in the 
acronym is considered as either vascular, infectious, or neuropathic (or combinations 
thereof). Early recognition and appropriate treatment of the high-risk foot would save limbs 
and improve patient quality of life. Infection is defined as critical colonization if superficial, or 
deep and surrounding wound infection based on the acronyms of NERDS (Non-healing 
wound, Exudate, Redness, Debris, Smell) and STONEES (Size increasing, Temperature, 
Os- to bone, New breakdown, Exudate, Erythema, Smell)(49). Patients with DM should be 
screened for these factors in a systematic manner whenever they are considered for HBOT.   
 
1.4 Hyperbaric oxygen therapy  
 
Hyperbaric oxygen therapy (HBOT) is a treatment designed to increase the body oxygen by 
administrating 100% oxygen at higher than atmospheric pressure. Henry’s Law dictates that 
the relationship between the volume of gas dissolved in a liquid or tissue and the partial 
pressure of that gas is proportional(50). Therefore, increasing atmospheric pressure will 
cause more oxygen to dissolve in the plasma, thereby maximizing tissue oxygenation (51). 
 
1.4.1 History of HBOT 
The use of oxygen at elevated pressures was first proposed for the treatment of 
decompression injury (52). Later, Churchill-Davidson et al described the use of elevated 
pressures and oxygen to potentiate radiotherapy in cancer patients in 1955 (53). In 1956, 
Boerema et al published a paper on the clinical use of hyperbaric oxygen to extend the 
duration of circulatory arrest during cardiac surgery (54). These publications were followed 
by reports of the clinical response to HBOT in patients suffering from Clostridial infections 
(54) and those poisoned by carbon monoxide (55). Within less than a decade, a diversity of 
medical disciplines were supporting the use of high oxygen tensions at pressure for the 







1.4.2 Mechanism of Action and HBOT Uses 
 
HBOT exerts its therapeutic effect by four mechanisms: mechanical effects, bacteriostatic 
effects, hyperoxygenation, and finally, the correction of hypoxia (58). Oxygen plays an 
important role in all cellular processes during wound healing, including cell metabolism, 
proliferation, and revascularization (56). Oxygen is also essential for increased antimicrobial 
activity, growth factor signal transduction, and collagen synthesis (56).  
 
Hyperbaric therapy has been used in the treatment of non-healing wound repair in chronic 
diabetic ulcers and delayed post-radiation tissue injuries. These disorders share many 
common elements, including chronic inflammation, reduced oxygen supply, stromal cell 
depletion, and fibrosis (59).  Hyperbaric therapy has been shown to promote angiogenesis, 
enhance fibroblast activity, augment formation of granulation tissue, reduce edema, and 
improve leukocyte function. Vasculogenesis is enhanced by HBOT-induced mobilization of 
stem cells from bone marrow (60). Neovascularization occurs by regional angiogenic stimuli, 
which influence the efficiency of new blood vessel growth by local endothelial cells (termed 
angiogenesis) and they stimulate the recruitment and differentiation of circulating 
stem/progenitor cells (SPCs) to form vessels de novo in a process termed vasculogenesis 
(61) (62). 
 
The activity of bone marrow endothelial nitric oxide synthase, which is required for SPCs 
mobilization, is diminished in DM (63). HBOT mobilizes SPCs in patients previously exposed 
to radiation and in diabetics (60). Moreover, HBOT mediated oxidative stress at sites of 
neovascularization will stimulate SPCs growth factor production by augmenting the synthesis 
and stabilization of hypoxia inducible factors (64). Extracellular matrix formation is closely 
linked to neovascularization and it is another oxygen-dependent process (65). 
 
HBOT was shown to increase the synthesis of vascular endothelial growth factor and it is the 
most specific growth factor for neovascularization (66). HBOT also stimulates synthesis of 
basic fibroblast growth factor (bFGF) and transforming growth factor β1 by human dermal 
fibroblasts (67), angiopoietin-2 by human umbilical vein endothelial cells (68), bFGF and 
hepatocyte growth factor in ischemic limbs and it up-regulates platelet derived growth factor 
(PDGF) receptor in wounds (69).  
 
HBOT has been demonstrated to have bacteriostatic and bactericidal effects. One study has 
demonstrated both pressure and hyperoxia to be important in the interaction between 




wound healing through development of a pro-inflammatory environment, but enhanced 
apoptosis can resolve the inflammation and support the progression of wound healing (70).  
 
There is growing evidence to support the promotion of bone repair with HBOT in chronic 
wounds with osteomyelitis. Osteoblast stimulation, anti-osteoclastic effects, and bone 
regeneration have been demonstrated using intermittent oxygen supplementation, providing 
mechanistic evidence for the adjunctive use of HBOT (71). Mader and Niinikoski 
demonstrated that the decreased oxygen tensions typically associated with bony infections 
could be returned to normal or above normal levels while breathing 100% oxygen in a 
hyperbaric chamber (72). Neutrophils require tissue oxygen tensions of 30-40 mmHg to 
destroy bacteria by oxidative killing mechanisms (73). HBOT has been proven effective as 
adjunctive therapy in animal models of chronic S. aureus and Pseudomonas aeruginosa 
osteomyelitis (74). Moreover, the transport of aminoglycoside (gentamicin, tobramycin, 
amikacin) across the bacterial cell wall is oxygen-dependent and is inhibited in conditions of 
a hypoxic environment when the tissue oxygen tensions are below 20 to 30 mmHg. 
Therefore, HBOT therapy may enhance transport and augment the antibiotic efficacy (75). 
This synergistic effect has also been shown for the cephalosporin class of antibiotics, where 
the combination of cefazolin and HBOT therapy produced a 100-fold greater reduction in 
bacterial counts than either antibiotic or HBOT therapies alone (76).  
 
1.4.3 Patient Selection for HBOT 
 
Patients with chronic wounds selected for HBOT usually have a history of non-
responsiveness to conventional treatments, including antibiotics and topical dressings, and 
failed debridement.  
 
Patient selection for HBOT can be assisted by noninvasive transcutaneous oxygen 
monitoring (TCOM) (56). HBOT is inappropriate when it is provided to patients who could 
heal without it, or when it is provided to patients who would most likely not benefit at all, or 
when an excessive number of treatments is provided to achieve the desired benefit (77).  
Most hyperbaric units select their patients based on TCOM measurements. 
 
1.5 Trans-Cutaneous Oxygen Measurement 
 
The appearance of commercial transcutaneous pO2 monitors in 1977, and transcutaneous 




technical innovation (78). The first ‘combined’ transcutaneous pO2 and pCO2 monitoring 
system was described in 1979 (79). 
 
Non-invasive TCOM can identify patients unlikely to heal spontaneously and most likely to 
benefit from HBOT. The IWGDF systematic review shows the most useful tests for predicting 
healing in an ulcerated patient were skin perfusion pressure (≥40 mmHg), toe pressure (≥30 
mmHg) and TCOM (≥25 mmHg) (80). 
 
Healing of an ulcer in a patient with peripheral arterial disease is related to the interplay of 
the severity of the perfusion deficit with other characteristics such as amount of tissue loss, 
presence of infection, mechanical load on the ulcer and other comorbidities (81). Patients 
with a toe pressure <30 mmHg or a TCOM <25 mmHg carry poor chance of healing and 
IWGDF suggest considering imaging and revascularization in these patients (82). However, 
it should be noted that peripheral arterial disease is not the only cause of reduced perfusion 
in a lower extremity, since edema and infection may also result in poorer tissue oxygenation, 
and these should all be treated accordingly (83) (84). 
 
1.6 Studies regarding HBOT in the management of DFU  
Many studies of the management of chronic wounds that included HBOT as component in 
the treatment have been undertaken during the past 45 years, including studies involving 
different types of lower limb ulcers. 
 
Kranke et al performed a Cochrane review of HBOT for chronic wounds, identifying 27 
potentially eligible trials, but excluded 17 based on quality (85). They found seven trials 
comparing HBOT as a treatment for diabetic ulcers with controls (68, 86-91), one study 
comparing HBOT with extracorporeal shock-wave therapy (92) and one study on HBOT for 
venous ulcers (93).  They concluded that there was some evidence that HBOT used 
adjunctively for diabetic wounds results in significant short-term improvement of wound 
healing by 6 weeks (85). 
 
Despite these findings, some studies found the opposite. For instance, a publication in 
February 2013 called “Lack of effectiveness of hyperbaric oxygen therapy for the treatment 
of diabetic foot ulcer and the prevention of amputation” by D.J. Margolis et al (94) contradicts 
the previous studies. However, several points of criticism against the study have been 
reported in a number of recent commentaries (95-97). These included the design of the 




commentaries stressed again that proper patient selection is a main predictor of the 
effectiveness of the treatment.    
 
1.7 Gaps in the literature and further studies needed 
 
HBOT has been used in the treatment of DFUs for more than 20 years, typically using the 
protocols described in the Undersea and Hyperbaric Medical Society guidelines (98).  
However, despite following the recommended protocols for patient selection and follow-up, 
there are still a number of patients who seem to be poor responders to the treatment.  It 
seems like further differentiation is required in patients who have already been selected for 
HBOT.  No such information is available in the literature, apart from the limited studies 
alluded to above. 
The identification of factors that may predict a poor treatment response is important.  If these 
factors are considered in addition to existing patient selection factors, it could potentially lead 
to the identification of additional modifiable risk factors that could be incorporated into the 
management protocol of patients in the unit, or a refined patient selection process could be 
implemented (in cases where these factors cannot be modified). 
 
1.8 Chapter conclusion 
 
This chapter reviewed the literature pertinent to DFU and how HBOT may directly address 
specific causative factors.  Although protocols for the selection of patients exist, a significant 
proportion of individuals do no respond to HBOT as expected.  Further stratification of 
patients may identify additional modifiable risk factors (and hence a requirement to include 
additional treatment regimens) or patients who would not respond to treatment may be 
identified and the selection of patients may therefore be improved further. 
This study aimed to explore these concepts at a busy HBOT unit, and the study methods will 
be addressed in the next chapter. 
 
In conclusion, the prevalence of DM is increasing in Bahrain and worldwide. Diagnosis of 
DM is based on fasting blood glucose, glycated haemoglobin or oral glycemic challenge. 
Complications are classified as macrovascular and microvascular. Diabetic foot ulcer is one 
of the complications and continues to increase worldwide causing huge economic burden on 
the government. Diabetic neuropathy and peripheral arterial disease are the major causes of 




is been used to treat DFU and that is for its known effect on angiogenesis, promoting 










Chapter 2: Study aim and objectives 
 
 
2.1 Study Aim and Objectives  
 
The main aim of this study was to assess potential factors that may influence the outcome of 
diabetic foot ulcers treated with an appropriate course of HBOT.  
 
The study thesis includes that this information may allow for more detailed and better 
selection of patients for HBOT and allow for better prediction of their response to therapy. 
 
2.1.1 Primary objectives 
 
The study therefore had the following primary objectives:  
1. To identify patients with a poor treatment outcome despite receiving an appropriate 
course of HBOT for DFU.  This included study participants: 
 with DFUs that do not show at least 30% reduction in the wound surface area in four 
weeks (at the end of 20 sessions of HBOT); or 
 requiring major amputation, including the ankle joint and above, within 3 months 
following completion of HBOT; or 
 who developed a new DFU on the same foot within 3 months following completion of 
HBOT 
2. To describe the association of different variables with the outcome of HBOT in 
patients who received treatment for DFU, including 
 Demographic variables, including age and sex; 
 Anthropometric variables, including height, weight and Body Mass Index; 
 Baseline blood test values (Creatinine level, Haemoglobin and Glycosylated 
Haemoglobin, White Cell Count and C-reactive protein); 
 Information about their diabetes, such as duration of their diabetes since diagnosis 
and co-morbid diseases the patient had been diagnosed with; 
 Transcutaneous Oxygen Measurement in the wound area, as described in 
international guidelines (99); 




 Information about ulcers such as cause (vascular, infection, pressure, burn or 
trauma) (100), site (toe, metatarsal, heel), depth (superficial, deep, to bone), Texas 
classification (101), NERDS and STONES criteria (102); 
 The presence or absence of foot deformities, such as clawing of the toes, hallux 
limitation, pes equinus, etc.); 
 History of vascular surgery in the lower limb and vascular assessment of the foot 
(presence or absence of pedal pulses, Doppler examination of foot pulses); and 
 Sensation assessment of the foot using a 10-g monofilament and the 60-second 
screening tool (103). 
 
2.1.2 Secondary objectives 
 
The secondary objectives of the study were based on the primary objectives and included: 
 
3. to identify predictors of “high risk patients” who may require additional care when 
receiving HBOT for DFU, and 
 
4. to identify predictors of “high risk patients” who would unlikely benefit from HBOT for 
DFU and should rather be selected out (patient stratification).  
 
2.2 Independent variables 
 
In order to determine whether any baseline information obtained from study participants 
could predict the outcome of this study (adequate or inadequate response to HBOT), the 
following variables were assessed in the cases and controls: 
 
Table 3.1 Independent variables evaluated in the study, their description and 
measurement 
Variable Description Measurement 
Age Age of the study participant at the time of 
starting HBOT 
years 
Sex The biological sex of the study participant Classified as male or 
female 
Height The height of the participant in centimetres 




Body Mass Index The weight of the participant in kilograms by 
the square of their height in metres 
Index 
Duration of diabetes The duration that the patient had been 
diagnosed with diabetes (from date of 
diagnosis to date of first consultation) 
Years 
Co-morbid diseases A list of all the co-morbid diseases with which 
the participant was diagnosed previously 
List of diagnoses 
Pedal pulses Whether the pedal pulses are present or 
absent during palpation as part of the clinical 
examination upon admission to the unit 
Dorsalis pedis pulse 
and/ or posterior 




The Doppler pulse wave of the dorsalis pedis 
and posterior tibial pulses  
Biphasic, triphasic or 
absent 
TCOM on air The lowest TCOM value measured in close 
proximity to the wound after breathing groom 
air 
Value in mmHg 
TCOM on oxygen The lowest TCOM value measured in close 
proximity of the wound after breathing 100% 
via face mask at sea level for 15 minutes. 
Value in mmHg 
TCOM with chamber 
challenge 
The lowest value of the TCOM after breathing 
100% oxygen at a pressure of 200kPa. 
Value in mmHg 
Vascular surgery Whether the participant has a history of 
previous vascular surgery (e.g. angioplasty) 
related to the lower limb 
A positive history was 
further elucidated by 




The laboratory-determined values of the 
following: 
 Baseline serum creatinine 
 Baseline HbA1c 
 White blood cell count 
 Hemoglobin level 
 C-reactive protein level 
The value obtained 
from the laboratory 
Presence or absence 
of neuropathy 
Assessment of sensation using the 60-second 
screening tool(103) and neuropathy is 
considered to be present if the participant was 
unable to detect four or more sensory 




challenges with the 10-g monofilament. 
Presence or absence 
of foot deformities 
Clinical evaluation of the patient to determine 
whether specific deformities are present, such 
as clawing of toes, hallux limitation, pes 
equinus, etc. 
Present or absent, 
with listing the specific 
deformity 
The cause of the 
wound 
Vascular, Infective, Pressure, Trauma or Burn The main causes for 
the wound is listed 
Pain The amount of pain the participant experienced 
upon admission, as measured with a visual 
analogue scale 
Rated from 0 to 10 
Ulcer site The anatomical site of the ulcer toe, hallux, metatarsal 
head, other 
Ulcer depth The depth of the ulcer (deepest) Superficial, deep, or 
to bone 
Ulcer duration The duration of suffering the ulcer as reported 
by the participant 
weeks 
Presence of other 
surrounding deep 
tissue injuries 
Whether the patient has other deep tissue 
injuries in the same foot 
Present or absent 
The stage of the 
wound 
Application of the Texas classification system 







Whether osteomyelitis is diagnosed on the foot 
X-rays performed 
Present or absent 
Charcot foot Whether Charcot foot is diagnosed on the foot 
X-rays performed 
Present or absent 
Sharp debridements The number of sharp debridements the patient 





The highest temperature in the area of the 





NERDS and STONEES criteria were applied Whether each of the 







Whether any micro-organism was cultured in 
the wound 
Yes/ no and the 
specific organism 
being listed 
Moisture balance The moisture balance of the wound in the 
wound, to indicate whether the wound is dry 
(moisture was added) or wet (moisture was 
taken away) 
added or taken away 
HBOT sessions The number of HBOT sessions received by the 
participant 
Numerical count 
Rate of wound 
healing 
The rate at which the wound was healing, as 
determined by using a 3-dimentional camera 
and progress is plotted with each visit.  
Percentage of wound 
reduced at the end of 
20 sessions 
Treatment outcome Classification of the individual participant as a 
“case” or “control” in accordance with the 
criteria provided above 


















Chapter 3:  Methodology 
 
3.1 Chapter Introduction 
 
The previous chapter detailed the aim and objectives of the study.  This chapter will provide 
details about the methodology that was followed to realize the aim and objectives.  It will 
describe the study design, as well as the setting in which the study was performed, so that 
appropriate extrapolations could be made to similar settings in future.  A detailed description 
of the study participants and how they were selected and the different variables that were 
measured is provided. 
The chapter will also indicate the way in which the data was obtained from study participants 
and how the data was managed, including the statistical analyses. 
The chapter concludes with the important ethical considerations that were pertinent in this 
study. 
3.2 Research Design 
 
This study employed a retrospective nested case control study to realize the aim and 
objectives of this study.  This design was used as the outcome is already available (healed 
or not healed), but the exposure of interest is not been studied. Because we were limited in 
the budget, time and availability of information we opted to use this study.  
 
3.3 Study Participants 
 
After excluding all the patients who received HBOT for indications other than DFU during the 
study period (01 January 2013 to 31 December 2018), a total of 246 patients met the 
inclusion criteria for the study and were treated for Diabetic Foot Ulcers (DFU) occurring 
below the level of the malleolus.  Their files were reviewed in more detail to determine 
whether they meet the inclusion and exclusion criteria. 
Figure 4.1 provides a flow-diagram indicating the flow of these participants in different 
phases of the study. A total of 83 combined patients received <20 treatment sessions 
(n=68), or received an unknown number of treatment sessions (n=15) as part of their 
treatment course and were thus excluded from the sample in accordance with the inclusion 
and exclusion criteria of the study.  A further 40 patients did not have follow-up information 

















Figure 4.1:  Flow diagram indicating the number of participants during different 
phases of the study. 
 
All patients who were seen at the King Hamad University Hospital (KHUH) in the Hyperbaric 
Oxygen Therapy (HBOT) unit were eligible for enrolment in the study if they met all of the 
following inclusion criteria: 
 
 Admitted to the unit between January 2013 and December 2018; 
 Received HBOT for DFU as indication; 
 Received the full workup in accordance with the existing unit protocols; and 
 Received advanced wound care (that means the patient has been evaluated using 
the advanced would evaluation and treatment modalities and been treated using the 
advanced wound care facility protocols and procedures) 
 
Exclusion criteria that were used in the study were: 
 Ulcers above the malleolus; 
 Patients who received less than 20 HBO treatment sessions; or 
 Patients for whom outcome information was not available in their clinical folders 
246 files reviewed 
Exclusion criteria applied: 
 <20 sessions (n=68) 
 Unknown number of 
sessions (n=15) 
 No outcome data (n=40) 
123 participants 
included in the analysis 




3.4 Outcome variables 
 
Once the full cohort of patients who received HBOT for DFU (as defined in the inclusion and 
exclusion criteria) were selected, we divided them into cases and controls, based on the 
following definitions: 
 
Cases:  Participants had an “inadequate response” to the HBOT, which was defined as:  
 Wounds that did not show at least 30% reduction in the wound surface area at the 
end of 20 sessions of HBO treatment (104); or 
 Participants requiring a major amputation, including the ankle joint, within 3 months 
following completion of HBOT; or 
 Participants who developed DFU on the same foot within 3 months following the 
course of HBOT 
 
Controls: All participants who did not fulfil the criteria defined above as an “inadequate 
response” were used as controls in the study.  
 
 
3.5 Study setting 
 
King Hamad University Hospital (KHUH) in the Kingdom of Bahrain represents one of the 
major tertiary hospitals. It harbours the biggest HBOT unit in the Middle East.  The unit was 
established in 2011 and has two different kinds of hyperbaric chambers, monoplace and 
multiplace chambers. A monoplace hyperbaric chamber is generally made of acrylic material 
to permit direct patient observation. Multiplace chambers are typically steel constructions in 
which more than one patient is pressurized at a time.  The multi-place unit at KHUH is 
certified for pressurization of eight patients per treatment session and it houses 5 monoplace 
chambers. 
 
The unit conducts approximately 4000 HBOT sessions per year, of which Diabetic Foot 
Ulcers (DFU) comprises the major proportion of indications for which treatment is provided.  
The unit is also linked to an advanced wound care facility that receives referrals from all 
other departments in the hospital and within the Kingdom. It encompasses 9 beds, of which 
6 are for ambulatory patients and the rest are designed to receive patients via ambulance. 




as Transcutaneous Oxygen Monitoring (TCOM) equipment, Ankle Brachial Pressure Index 
(ABPI), an 8MHz handheld Doppler and infra-red thermometers. 
 
Patients are referred to the unit from within the hospital, as well as from practitioners outside 
the hospital.  All patients are consulted by a medical practitioner who is qualified in providing 
HBOT and is supported by the wound care personnel in case of patients referred with 
wounds.  Patients are evaluated in line with international guidelines for wound management 
(in the wound care centre) and some of them may be selected for adjunctive HBOT if they 
meet the international criteria and guidelines.   
 



























Diabetic Foot Ulcer 
TCOM breathing 








TCOM breathing 100% 
oxygen at 100kPa 
TCOM >100mmHg 
TCOM 40 – 100mmHg 
TCOM breathing 100% 
oxygen at 240kPa TCOM <100mmHg 
TCOM >200mmHg TCOM 100 – 200mmHg 




The HBOT sessions are provided once daily for patients, five days per week.  Standardised 
unit protocols (based on the international guidelines) are used in the selection and 
management of patients.  This includes standardized unit documentation to capture clinical 
information. 
 
3.6 Data Sources and management 
 
As part of this process, a study number was assigned for each individual and no personal 
identifying information was captured.  All information required for this study was captured in 
a single sitting for any one patient, to ensure access to the records are not required again.  
The patient treatment logs were used as sampling frame.   
 
The clinical records of the patients consisted of the clinical notes (captured by the treating 
physician), the side-room investigations as captured by the nursing personnel of the unit, the 
detailed wound assessment information that consists of standard patient information capture 
sheets for systematic assessment, the laboratory information of all special investigations 
performed, including X-ray reports and the detailed log sheets of all the HBOT sessions the 
patient received. 
3.7 Sample size calculation 
 
In order to maximize the power of the study to detect a difference between cases and 
controls, the study aimed to include all individuals (n=246) who were treated at the facility 
during the study period – provided they meet the inclusion and exclusion criteria.  All 
individuals (n=123) who met the criteria for classification of cases (inadequate response to 
treatment) were included in the study and the rest of the individuals were all classified as 
controls. 
3.8 Quantitative Variables 
 
Quantitative variables in this study were summarized as means (with standard deviations) or 
as medians (with interquartile ranges) if the data was not normally distributed.  Population 







3.9 Statistical methods 
 
Data were presented in graphs and tables.  Differences between cases and controls were 
determined using the following statistical methods: 
 Numerical variables were compared by using the F-test for comparison of the 
variances and then using the T-test to compare the mean values in the populations, 
assuming equal or unequal variances as determined by the F-test.  If the data was 
not normally distributed (as determined by means of normality plots), the Wilcoxon 
rank-sum test was used. 
 Categorical variables were compared using the Chi-squared test of contingency 
tables.  The 2x2 tables were additionally evaluated by calculating the Odds Ratio 
(with 95% confidence intervals).  Whenever the individual cell frequency assumptions 
were violated, the Fisher’s exact test was used.  If one of the cells in the 2x2 table 
was empty, the method for approximation as described by Cornfield was used to 
allow for statistical analysis (105). 
 Percentages and proportions were compared using the Z-test. 
 
All of these statistical procedures were performed using the Stata statistical software 
package (Stata corp).  A significance level of 0.05 was used in all statistical tests. 
 
A binary logistic regression model was developed by inserting all independent variables that 
were statistically significantly associated with the outcome variable (p<0.05).  This was 
performed using the SPSS statistical software package. 
 
3.10 Ethics considerations 
 
The study was approved by the King Hamad University Hospital ethics committee 
(reference: KHUH/Research/No.227/2018). 
 
The study complied with the international legal and ethical principles as contained in the 
Declaration of Helsinki (106).  The main ethics consideration of concern in this study was the 
principle of autonomy.   
The international guidelines requires that informed consent must be obtained from the 
patients before participation in research.  However, in considering this particular study, it was 
exceptionally difficult to obtain consent from study participants, since they had all been 




across the Kingdom of Bahrain and other countries in the Middle East.  The investigators 
therefore submitted a motivation and request for waiver of informed consent.  At the same 
time the particular importance of maintaining absolute confidentiality in this context in order 
to protect the individuals was stressed.   
 
In order to ensure confidentiality, no identifying personal information was captured during 
this study.  Also, the only persons who had access to the primary data (patient files) were 
the individuals who treated these patients and thus generated the information.  No additional 
persons had access to the medical information captured in the.  The primary investigator 
captured all the information directly from the patient files into the spreadsheet and the 
database therefore only contained de-identified information.  Only this de-identified 






Chapter 4: Results 
 
4.1 Chapter Introduction 
 
This chapter will first describe the demographic profile and descriptive statistics of the study 
participants, and then provide the results of the analytical statistical analyses.   
 
4.2 Descriptive statistics 
 
4.2.1 Patient characteristics 
 
The sample cohort (n=123) comprised 22 females and 101 males.  Figure 4.2 shows the 
proportion of study participants that were male and female. Males represented majority of 
the participants with only 18% of participants being female.  
 
Figure 4.2: Distribution of patient characteristics by sex  
Additional demographic, anthropometric and laboratory data of the study participants are 





Table 4.1. Demographic, anthropometric and laboratory data of all study 
participants (N=123) 
Variable N (missing) mean (SD) Median (IQR) 
Age (years) 123 (0) 58.2 (10.1) 58.1 [51,17 - 64,98] 
Height (cm) 79 (44) 171.7 (8.6) 173 [165.5 - 177.7] 
Weight (kg) 79 (44) 86.4 (14) 86.3 [77.65 - 94.6] 
BMI 79 (44) 29.3 (4.6) 28.4 [26,19 - 33,09] 
DM duration (weeks) 118 (5) 18.5 (8.5) 20 [11 - 24,5] 
Creatinine level 103 (20) 138.7 (150.5) 96.5 [83,36 - 121,56] 
Baseline HbA1c (%) 100 (23) 8.8 (1.7) 8.5 [7,6 - 9,63] 
Baseline WBC  102 (21) 11.2 (4.5) 11.4 [7,67 - 13,66] 
Baseline haemoglobin 103 (20) 11.8 (1.7) 11.7 [10,6 - 13,1] 
Baseline CRP (mg/l) 82 (41) 87.4 (100.1) 45 [16,32 - 150,7] 
No of HBOT sessions  123 (0) 27.1 (7) 27 [20 - 30] 
 
Table 4.2 compares the demographic, anthropometric and laboratory results of cases (those 
with an “inadequate response” to HBOT) and controls (those who responded optimally). No 
significant difference were found in age, sex, height, weight, or body mass index between 
cases and controls (p>0.05).  There were also no significant differences in their creatinine, 
C-reactive protein and HbA1c levels (p>0.05).  However, cases had significantly higher white 
blood cell counts and lower haemoglobin levels compared to controls (p<0.05).  The 






Table 4.2:  The demographic, anthropometric and laboratory results in the cases and 
controls 
Variables 
Cases (n= 75)  
Mean ± SD 
Median [IQR] 
Controls (n=48) 
Mean ± SD 
Median [IQR] p-value 
Participant age (years) 58.4 ± 10.1 57.8 ± 10 0.764 
Proportion who is male 64 / 75 11 / 48 0.295 
Duration of DM 20 [12-22] 20 [10-25] 0.615 
Weight (kg) 86.2 ± 14.4 86.6 ± 13.7 0.898 
Height (cm) 171.9 ± 7.1 171.6 ± 10.2 0.873 
Body Mass Index (kg/ cm2) 28.3 [25.6-32.9] 28.4 [27.1-33.2] 0.542 
White blood cell count 11.9 ± 4.9 10.1 ± 3.7 0.038 
Haemoglobin level 11.4 ± 1.7 12.3 (± 1.7 0.009 
Creatinine level 100.9 [84.7-124.8] 93 [80.4-117] 0.175 
HbA1c 8.4 [7.9-9.8] 8.6 [7.6-9.4] 0.595 
C-Reactive Protein mg/L 47.6 [16.2-194] 39.5 [16.5-66.5] 0.232 
 
4.2.2 Outcome variables 
 
Of the 123 study participants, (61.0%, n=75) of the study participants had an “inadequate 
response” to HBO therapy, yielding 48 controls for comparison.  The cases comprised sixty-
five individual participants who had a single “inadequate response” item that designated 
them as cases.  Of these individuals, 72% (n=54) did not have 30% reduction in their wound 
areas, 13.3% (n=10) had a new DFU within 3 months following their treatment and one 
individual had an amputation above the ankle within 3 months following the treatment.  A 
further 10 study participants had two “inadequate response” items that designated them as 
cases (six individuals had less than 30% reduction in the size of their wounds and also had 




developed a new wound within three months and one individual had a new DFU and 
amputation within three months following treatment). 
 
4.2.3 Predictive variables and analytical statistics 
 
Table 4.3 Shows the results of TCOM measurements on air an after 15 minutes of breathing 
100% oxygen via face mask, pain score and ulcer duration, none of which showed 
significant differences between cases and controls. Conversely, cases had a significantly 
higher infrared thermometer reading compared to controls (p=0.001).   
 
Table 4.3:  TCOM, pain score, ulcer duration and infra-red thermometer readings in 
cases and controls.  
Variables 
NOH (n= 75)  
Mean ± SD) 
Median [IQR] 
OH (n=48) 
Mean ± SD 
Median [IQR] 
p-value 
Lowest TCOM (mmHg) 39.5 ±16.3 39.3 ± 15 0.944 
Lowest TCOM after  15 mins O2 
by face mask (mmHg) 
110 [88-148.8] 103.3 [83.5-145.5] 0.685 
Pain score 3.5 [2-6] 3 [2-5] 0.924 
Ulcer duration (weeks) 2 [1-4] 2 [1-3] 0.340 
Infrared thermometer (°C) 5.5 [4-7] 3.5 [2.3-5] 0.001 
 
4.2.4 Comorbidities  
Only 15% of patients (n=18) had DM with no other comorbid conditions captured in their 
clinical files. The majority of the patients (n=100 (85%)) had at least one comorbid condition.  
Figure 4.3 represents the number of participants presenting with specific comorbidities (with 
many patients having more than one comorbidity).  The majority of the patients (n=85) had 
hypertension as comorbidity of their DM. Diabetic nephropathy and hypothyroidism were not 







Figure 4.3: The number of patients with comorbidities. Numbers on the bars represent 
the number of the patients for each comorbidity.  
 
Table 4.4 Comparison of comorbid diseases between cases and controls 
 Cases Controls p-value 
Hypertension 72% 67% 0.626 
Hyperlipiaemia 39% 44% 0.723 
Chronic kidney disease 14% 21% 0.680 
Diastolic dysfunction 3% 2% 0.960 
Diabetic retinopathy 15% 15% 1.000 
Hypothyroidism 1% 2% (insufficient observations) 
Diabetic neuropathy 1% 2% (insufficient observations) 
Ischaemic heart disease 16% 19% 0.857 
Peripheral vascular 
disease 
9% 4% 0.817 
On renal dialysis 8% 4% 0.848 





The causes of the wounds did not differ between cases and controls (p>0.05).  The details of 
the causes of the wounds of study participants are contained in Table 4.5..  Likewise, the 
sites of their diabetic foot ulcers and the depth of their ulcers did not show statistically 
significant differences (see Table 4.6). 
 




























Likewise, the sites of their diabetic foot ulcers and the depth of their ulcers did not show 
statistically significant differences (see Table 4.6). 
 







Toe 44 (59) 28 (37) 0.978 
Metatarsal 24 (32) 22 (29) 0.336 
Heel 20 (27) 6 (8) 0.472 
Depth    
Superficial 8 (11) 13 (17) 0.368 
Deep 48 (64) 27 (36) 0.509 








Table 4.7: Texas classification of wounds, NERDS, STONEES and presence of 
foot deformity in cases (n=75) and controls (n=48) 















































Os: Probe To Bone 





































































4.2.5 Diabetic Foot Ulcers of the study participants 
 
Study participants with superficial ulcers were more likely to have a good response to HBOT 
(Odds Ratio = 0.3; 95% Confidence Interval: 0.1 – 0.8; p=0.018), while those with deep 
ulcers were more likely to be designated as cases.  The number of patients who had smelly 
wound when applying to the “STONEES criteria” were significantly higher in cases compared 
to controls. Likewise, when applying the “NERDS criteria”, cases were more likely to present 
with non-healing wounds than controls (see Table 4.7).   
Cases were more likely to present with deformities of the foot than controls, Odds Ratio of 
2.6 (95% Confidence Interval: 1.2 - 5.5).  Conversely, participants who had no abnormality 
reported on the foot X-ray had a significantly lower risk of presenting with an inadequate 
response to treatment, with an Odds Ratio of 0.3 (95% Confidence Interval: 0.1 – 0.7; 
p=0.007). 
4.3 Binary logistic regression model 
 
The binary logistic regression model is summarized in Table 4.7, while Table 4.8 indicates 
the model classification of cases and controls. 
 
Table 4.8 Regression model summary 
Step -2 Log likelihood 
Cox & Snell R-
square 
Nagelkerke R-square 
1 107.625* 0.236 0.320 
* Estimation terminated at iteration number 5 because parameter estimates changed by less than 
0.001 
Table 4.9 Regression model classification table 
 Predicted Percentage 
correct Observed Cases Controls 
Cases 49 11 81.7 
Controls 13 27 67.5 





The variables that were included in the model are depicted in Table 4.9 
Table 4.10 Variables included in the regression equation 
 95% CI for Exp (B) 
Variable B S.E. Wald df Sig. Exp (B) Lower Upper 
White Cell Count  .111 .061 3.333 1 .068 1.1118 .992 1.259 
Haemoglobin -.321 .146 4.835 1 .028 .725 .545 .966 
Temperature .073 .114 .411 1 .522 1.076 .860 1.345 
STONEES (N) (missing)   4.506 2 .105    
STONEES (N) (No) -2.633 1.269 4.304 1 .038 .072 .006 .865 
STONEES (N) (Yes) -1.692 .916 3.410 1 .065 .184 .031 1.109 
STONEES (S) (missing)   1.784 1 .182    
STONEES (S) (Yes) -.729 .546 1.784 1 .182 .482 .165 1.406 
Foot deformity (Yes) -.827 .511 2.617 1 .106 .437 .161 1.191 













Because DFU is commonly associated with infection, it is not surprising that a high WBC 
count (indicating more severe infection) is associated with poor response to HBOT.  
Infectious states involving aerobic organisms are known to deplete oxygen reserves in the 
body and may thus actively work against the delivery of additional oxygen with HBOT in the 
wound area. 
 
A number of other findings in our study was also not unexpected.  It is well known that 
anemia increases the risk of foot complications in patients with DFU(110). Cases (individuals 
with a poor response to HBOT in our study) had significantly lower hemoglobin levels than 
controls. A low hemoglobin level in diabetic patients could be due to low iron levels, or be 
secondary to chronic renal failure, but may also be due to the body’s response to infection.  
This creates difficulty in providing advice on whether this should be corrected in patients if 
detected at baseline, because some authors suggest that iron levels should not be corrected 
in patients with a current infection(111). 
 
Inflammation is a fundamental part of the wound healing process and recruitment of 
neutrophils is mandatory for the clearance of microorganisms. In our study, we found that 
elements indicating a heightened inflammatory process were raised in the cases, including 
the WBC count, infrared thermometer reading, smell of the wound and new breakdown 
(typically due to hidden infection). This indicates that poor control of an infection causes 
delay in wound healing. This may be due to patient factors (such as immunity), wound care 
factors or an ulcer factor such as the Neutrophil Extracellular Trap (NET). NET is a natural 
response against infection, but excess or deregulated NETosis can cause tissue 
damage(112). One type of NETosis is responsible for reactive oxygen species (ROS) 
generation (113). One study (114) proposed that therapeutic strategies aimed to modulate 
NETosis should be pursued to improve the outcome in DFU patients. 
 
Many studies have reported a positive effect of HBOT in the treatment foot ulcers in patients 
with DM. However, there are some studies that reported no positive effect of using HBOT in 
the treatment of DFU (107).  This study was not performed to determine whether HBOT is 




context of patients who had already been selected for HBOT using standard international 
selection criteria, mainly based on Transcutaneous Oxygen Monitoring (TCOM) results. 
 
Within this context, there are very few studies that assessed the factors that may influence 
wound healing and the response to HBOT in patients with DFU (108) (109).  For this reason, 
the objective of the current study was to determine potential factors that may influence 
wound healing response when using HBOT in patients with DFU.   
 
When considering the conditions that define an “inadequate response to HBOT” in the study, 
it was surprising to see the high proportion of cases compared to controls, amounting to 
60.98% of the study participants.  The majority of these cases were due to less than 30% 
closure of the wound area, while some developed new ulcers and/ or required an amputation 
at the level of the ankle or above.  This high percentage of “inadequate responses” highlights 
the need for improved selection of patients for HBOT.  It would also explain why some 
authors question the value of HBOT for DFU(107).  These findings should however be 
interpreted with caution, as highlighted in the section below. 
 
A number of anthropometric and laboratory measurements are routinely performed on 
patients in the unit.  It was surprising to see that very few of these could be used to predict 
the response to HBOT.  None of the demographic or anthropometric measurements could 
predict the outcome of the treatment.  An increased body mass index would suggest a 
higher pressure on an ulcer when the patient is walking, but this seemed not to be an 
important factor in our study. 
 
We found that a high white blood cell (WBC) count, a low hemoglobin (Hb) level, and high 
infrared thermometer readings were baseline tests that were statistically associated with the 
cases.  Upon clinical examination, we likewise found that new wound breakdown, chronic, 
non-healing wounds and increased smell of a wound to be factors associated with an 
inadequate response to HBOT.  The combination of these factors seem to point to ongoing 




Neither age nor gender was related to the outcomes in our study. These findings are 
consistent with the findings of a previous study(115). However, there are studies that have 
found an association with age and demonstrated that patients who achieved better 





A history of uncontrolled diabetes results in a high number of patients with diabetic 
complications such as peripheral arterial disease, neuropathy or nephropathy. As expected 
in a diabetic population, a large proportion of the patients in our study received angioplasty 
before presenting at our unit or required angioplasty as part of their treatment.  Peripheral 
arterial disease is an important risk factor for impaired wound healing and lower extremity 
amputation(117). Hokkam assessed the impact of risk factors on the outcome of diabetic 
foot ulcers and identified that peripheral arterial disease is significantly related to the 
development of ulceration but not to the ultimate outcome of the wound (118) 
 
The Wagner grading of ulcers is commonly used in the assessment of patients with DFU for 
HBOT.  Previous studies observed a poorer outcome in patients with Wagner grade 3 
classification or above.  Our study findings were consistent, but not statistically significant 
(119).  The reason for the findings in our study is most likely based on a selection bias, since 
Wagner grade 3 and above would typically be the type of patients that will be selected for 
HBOT at the unit. 
 
The number of treatments received was not found to be significantly related to the ultimate 
outcome in our study. This is in contrast to a study that observed that 73.8% of patients 
improved with a mean number of 34 HBO treatments and that patients who did not improve 
received a mean number of 24 HBO (119). Another study proposed that 30 – 40 HBOT 
sessions are common for DFU. The Undersea and Hyperbaric Medical Society do not 
recommend a specific number of treatment sessions, but they do advise practitioners to re-
evaluate the patient and the wound after 30 days of treatment and to proceed with further 
treatment sessions if indicated.  Our study likely did not find a significant difference in the 
number of treatment sessions because standardized unit protocols are used in the 
treatment.  It is however important to interpret the association between the number of 
treatment sessions and healing as an outcome with caution.  A low number of treatment 
sessions may be associated with a poor outcome because of a poor response overall and a 
clinical decision to stop treatment.  On the contrary, a high number of treatment sessions 
may be associated with a poor response when clinicians opt to continue with HBOT despite 
evidence that there is no response.  It is therefore important for future studies to identify 
objective measures that would guide clinicians in advising additional treatment sessions 
beyond the proposed 30-40 HBOT sessions.   
 
In conclusion, this study points out factors that influence wound healing in patients receiving 




are very crucial to improve the outcomes in DFU patients. Of these, it seems like aggressive 
management of infections is important to ensure an adequate response to HBOT.   
 
5.2 Strengths and limitations of the study 
 
One of the strengths of our study is that the hyperbaric facility has a world-class advanced 
wound care unit.  Both of these units have standardized approaches to patient selection and 
patient care and make use of standardized documents to capture patient information and 
guide their management.  This allowed for the availability of rich patient data.  Nonetheless, 
the information that were captured had the clinical management of the patients in mind, 
rather than future research and (like all retrospective studies) our study could be subject to 
information bias.  Information that the clinical personnel may not have thought to be 
important in the clinical management of the patient may thus be omitted from the clinical 
notes, including potential important negative findings in the patient histories.  Patients may 
also present their history in general terms and approximations.  For instance, patients may 
round the duration of their illness up or down and not provide the exact figure.  For this 
reason, our study included objective measures obtained during the initial consultation, 
including laboratory results and the objective wound assessment protocols.   
 
Some data was missing on individuals that may have been included in the study.  It is 
unclear whether this information is more likely to be missing in cases or controls.  Informal 
discussion with the unit personnel seem to indicate that this may be the case.  Positive 
findings are generally listed for individuals who do not respond well, while patients who are 
discharged from the unit (following successful treatment), may not have this information 
specifically mentioned in their files.  The fact that outcome data was missing for a large 
number (n=40) individuals may explain the high number of cases (compared to controls) in 
our study. 
 
The selection of controls is an important consideration in all case-control studies.  Our study 
used all available patients as study participants.  This would normally reduce the risk of 
selection bias.  However, our selection was based on the availability of specific outcome 
information and if the missing data is associated with the outcome, there may be a systemic 
error in our study findings. 
 
Despite the weaknesses mentioned above, this study also had a number of strengths.  The 




the patients at the time of measuring the independent variables.  The unit also utilizes 
standardized documentation when examining and treating patients.  This is the case for the 
HBOT facility, as well as the wound care unit.  Many of the measurements are based on 
objective findings, including laboratory tests.  The risk of measurement bias is thus very low 
in this study. 
 
The classification of cases and controls were based on objective measurements, including 
the measurement of wound sizes using a 3-dimentional camera with software that plots the 
progress with each visit.  New wounds and amputations are also objective findings used for 




One of the major factors that would contribute to increase the risk of infection in diabetic 
patients is poor glycemic control. A strict control of blood sugar is recommended for the 
treatment of DFU. Also, patients with infrared reading of three degrees or more deserve to 
be admitted for an intravenous antibiotic before the infection presents clinically in form of 
redness or induration.  
Anemia which could be difficult to treat, should be addressed before commencing the 
treatment. Simple iron deficiency anemia can be treated with iron replacement therapy. 
However, patients with anemia secondary to chronic kidney disease should be referred for 
erythropoietin treatment.  
  
The usefulness of HBOT in the treatment of DFU has not yet been fully elucidated and it is 
possible that additional factors may be used in the assessment of patients in order to 
improve patient selection.  Our study suggests that patients who are selected for HBOT in 
accordance with existing patient selection criteria as recommended by the UHMS can be 
stratified further by focusing particularly on infection in the wound and to ensure that this is 
adequately addressed.  Ongoing infection seems to be a likely explanation for a poor 
response to HBOT. 
5.4 Further studies 
 
Our study did not measure long-term outcomes of patients receiving HBOT for DFU.  Future 
prospective studies should consider long-term follow-up of patients to determine whether 
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